Advancements in Prostate Diseases Treatment

Dear Colleagues,

The field of prostate diseases treatment has witnessed in the last decades significant innovations including evolving pharmacological strategies and novel minimally invasive therapies for benign prostatic hyperplasia, developments in surgical management of prostate cancer etc. This is one of the more dynamic chapters, undergoing rapid transformation and evolution. Developments such as robotic surgery, focal therapies, next-generation imaging, PSMA-targeted diagnostics or theranostics are shifting paradigms, clinical algorithms and patient outcomes. More than these, biomarkers and genetic profiling contribute to precision medicine approaches, enabling individualized treatment planning and improved risk stratification. Significant data regarding novel technologies such as Rezum, Aquablation or ThuLEP are accumulating, creating premises for challenging the current Guidelines and refining clinical decision-making. Artificial intelligence is rapidly transforming the landscape of prostate disease management by improving diagnostic accuracy, optimizing risk stratification, and supporting precision-guided treatment decisions across the care paradigms. In addition, machine learning–based predictive models and radiomics are increasingly integrated into imaging interpretation and therapy response assessment. 

The issue welcomes original research, expert perspectives, technical innovations, and clinical outcome studies addressing novel surgical techniques, therapeutic developments, quality-of-life outcomes, and health system impacts in the management of prostate disease. A special emphasis is placed on technologies that hold the potential to redefine standards of care and clinical pathways.